Health

The digital therapeutics company earned a first-of-its-kind FDA breakthrough designation for its BiovitalsHF heart failure DTx—we unpack how the FDA is opening up the opportunity for DTx vendors to take the same road.

Monitoring adhesives could stick out in the RPM market: Remote monitoring startup BioIntelliSense scored $45M for its vital monitoring stickers—here’s why less-frillywearable products like itcould carve a sticky spot in the ballooning remote patient monitoring market.

​​Virtual mental healthcare is becoming need-to-have for digital health cos: D2C telehealth giant Ro is launching virtual mental health services—this marks yet another digital health co branching into the budding market opportunity in virtual mental healthcare.

Anthem, Humana JV could be a golden distro channel for DTx makers: The payers are developing a cloud-based pharmacy benefits management platform,—we unpack why its pricing transparency feature makes it a good choice for DTx vendors trying to get their therapies on drug formularies.

Happify Health launched the first-ever prescription digital therapy for anxiety and depression, giving it a competitive edge over its peers—but if DTx companies want doctors to prescribe their apps, they’ll need insurers on their side.

Unraveling the healthcare pricing transparency knot: Healthcare pricing transparency startup Turquoise Health scored $5 million in funding—and even though it’s in its early stages, it’s primed to disrupt healthcare pricing amid myriad attempts from the gov’t to do the same.

Taking social determinants of health programs to the next level: UnitedHealthcare dropped $11.4 million into social health programs across the US—we unpack why that’s not enough to generate a meaningful healthcare impact.